DGS Capital Management LLC Invests $143,000 in Bausch Health Companies Inc. (NYSE:BHC)

DGS Capital Management LLC bought a new stake in Bausch Health Companies Inc. (NYSE:BHC) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 17,745 shares of the company’s stock, valued at approximately $143,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Dimensional Fund Advisors LP raised its holdings in shares of Bausch Health Companies by 12.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,165,512 shares of the company’s stock valued at $22,063,000 after purchasing an additional 341,936 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in Bausch Health Companies by 2.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 246,808 shares of the company’s stock worth $1,719,000 after buying an additional 4,944 shares during the last quarter. Mackenzie Financial Corp lifted its holdings in Bausch Health Companies by 111.0% during the 2nd quarter. Mackenzie Financial Corp now owns 2,381,888 shares of the company’s stock worth $16,612,000 after buying an additional 1,252,834 shares during the last quarter. Clearline Capital LP purchased a new position in shares of Bausch Health Companies in the 2nd quarter valued at about $6,881,000. Finally, Creative Planning increased its holdings in shares of Bausch Health Companies by 16.9% in the 3rd quarter. Creative Planning now owns 55,351 shares of the company’s stock valued at $452,000 after acquiring an additional 7,995 shares during the last quarter. 78.65% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Evercore ISI raised Bausch Health Companies to a “hold” rating in a report on Tuesday, October 15th. Royal Bank of Canada increased their target price on shares of Bausch Health Companies from $10.00 to $11.00 and gave the company a “sector perform” rating in a research report on Friday, November 1st. Finally, StockNews.com raised shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a research report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, Bausch Health Companies has an average rating of “Hold” and an average price target of $7.75.

Bausch Health Companies Stock Down 1.1 %

NYSE BHC opened at $7.73 on Monday. The firm has a market cap of $2.79 billion, a P/E ratio of -16.09 and a beta of 0.69. Bausch Health Companies Inc. has a 52-week low of $3.96 and a 52-week high of $11.46. The business’s 50-day moving average price is $7.83 and its 200 day moving average price is $7.46.

Bausch Health Companies (NYSE:BHC) last announced its earnings results on Wednesday, October 30th. The company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.10. Bausch Health Companies had a negative return on equity of 755.86% and a negative net margin of 1.88%. The company had revenue of $2.51 billion for the quarter, compared to the consensus estimate of $2.42 billion. During the same period last year, the business posted $1.03 EPS. The company’s revenue was up 12.2% on a year-over-year basis. As a group, analysts anticipate that Bausch Health Companies Inc. will post 3.73 earnings per share for the current year.

Bausch Health Companies Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.